QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents

This Article Full Text Full Text (PDF) All Versions of this Article: 10/1/32    most recent 15228517-2007-042v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (1) Citing Articles via Google Scholar Google Scholar Articles by Panigrahy, A. Articles by Blüml, S. Search for Related Content PubMed PubMed Citation Social Bookmarking                   What's this?

Metabolism of diffuse intrinsic brainstem gliomas in children

Department of Radiology (A.P., M.D.N., S.B.), Childrens Center for Cancer and Blood Diseases (J.L.F., R.S.), Division of Neurosurgery (M.D.K.), Department of Neuropathology (F.H.G.), Childrens Hospital Los Angeles, Los Angeles, CA; and Rudi Schulte Research Institute, Santa Barbara, CA (S.B.); USA

Address correspondence to Stefan Blüml, Childrens Hospital Los Angeles, Department of Radiology, MS 81, 4650 Sunset Boulevard, Los Angeles, CA 90027, USA (sbluml{at}chla.usc.edu).

Progress in the development of effective therapies for diffuse intrinsic brainstem gliomas (DIBSGs) is compromised by the unavailability of tissue samples and the lack of noninvasive markers that can characterize disease status. The purpose of this study was to compare the metabolic profile of DIBSGs with that of astrocytomas elsewhere in the CNS and to determine whether the measurement of metabolic features can improve the assessment of disease status. Forty in vivo MR spectroscopy (MRS) studies of 16 patients with DIBSG at baseline and after radiation therapy were retrospectively reviewed. Control data for baseline studies of DIBSGs were obtained from 14 untreated regular and anaplastic astrocytomas. All spectra were acquired with single-voxel, short echo-time (35 ms), point-resolved spectroscopy. Absolute metabolite concentrations (mmol/kg) and lipid intensities (arbitrary units) were determined. At baseline, creatine and total choline (tCho) were significantly lower in DIBSGs than in astrocytomas elsewhere in the CNS (4.3 ± 1.1 vs. 7.5 ± 1.9 mmol/kg, p < 0.001; 1.9 ± 0.7 vs. 4.2 ± 2.6, p < 0.001). Serial MRS in individual subjects revealed increasing levels of tCho (p < 0.05) and lipids (p < 0.05) and reduced ratios of N-acetylaspartate, creatine, and myoinositol relative to tCho (all p < 0.01). Metabolic progression defined by increased tCho concentration in serial MRS preceded clinical deterioration by 2.4 ± 2.7 months (p < 0.04). Low tCho of DIBSG at baseline is consistent with low proliferative tumors. Subsequent metabolic changes that have been associated with malignant degeneration preceded clinical deterioration. MRS provides early surrogate markers for disease progression.

Key Words: brainstem gliomas • disease progression • metabolism • MR spectroscopy • pediatrics

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				Z.A. Seymour, A. Panigrahy, J.L. Finlay, M.D. Nelson Jr, and S. Bluml Citrate in Pediatric CNS Tumors? AJNR Am. J. Neuroradiol., May 1, 2008; 29(5): 1006 - 1011. [Abstract] [Full Text] [PDF]